Project Description

Cannabidivarin, also known as CBDV, is a non-psychoactive cannabinoid found in minor amounts in the hemp plant Cannabis sativa.

A recently discovered cannabinoid, CBDV has been the subject of much research into its potential therapeutic properties:

A study led by GW Pharmaceuticals in collaboration with the University of Reading suggested cannabidivarin strongly suppressed seizures in six different experimental models commonly used in epilepsy drug discovery. There are countless studies on CBDV and its anti-covulsant affects, specifically on Epilepsy.

Official Research Reports

Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. (Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ, 2014)

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. (Naoki Amada, Yuki Yamasaki, Claire M Williams, Benjamin J Whalley, 2013)

Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. (Rock EM, Sticht MA, Duncan M, Stott C, Parker LA, 2013)